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Abstract 
A lateral flow (LF) device combined with
quantum dots (QDs) technology was developed
for rapid detection of a specific mycobacterial
flavoprotein reductase (fprA). In order to
develop the LF assay based on a double-anti-
body sandwich format, two monoclonal anti-
bodies recognizing different epitopes located
in separated fprA domains were identified. The
first monoclonal antibody was immobilized
onto the detection zone of a porous nitrocellu-
lose membrane, whereas another monoclonal
antibody was conjugated to QDs nanoparticles
as a detection system. Using these monoclonal
antibodies we recorded a good fluorescence
signal, the intensity of which was directly pro-
portional to the concentration of fprA protein.
The use of antibodies conjugated with fluores-
cent semiconductor QDs via biotin-strepta-
vidin bridge, allowed the detection of fprA pro-
tein at concentrations as low as 12.5 pg/μL in
less than 10 min. The reported technology
could be useful in the diagnostic investigation
of Mycobacterium tuberculosis and other
human pathogens in clinical specimens.
Introduction
In the past few years, the LF immunoassay-
based technology has become a powerful tool
in the rapid detection of pathogens in liquid
samples.1
Originally this technique was used as a preg-
nancy test but nowadays several kits based on
LF technology have been developed for a large
number of pathogens, toxins or drugs.2-8 LF
technology provides qualitative information on
the presence/absence of an analyte in a liquid
sample with several advantages, including
reduced time, low cost and possibility of per-
forming on field assays, thus avoiding any sam-
ple transport.1 All these features make LF tech-
nology an interesting tool for diagnostic inves-
tigation of Mycobacterium tuberculosis. The
last decade has seen a dramatic resurgence in
the incidence of tuberculosis and related
mycobacterial diseases, especially in poorer
areas but also in developed world.9 Indeed,
diagnosis of mycobacterial infections requires
rapid assays for immediate therapy or treat-
ments for disease prevention.10 Diagnostic
investigations of mycobacterial infection are
currently mostly based on microscopic analysis
via the Ziehl-Neelsen or Auramine-rodhamine
staining and culture isolation.11 Even though
microscopic investigations are relatively rapid,
they have several disadvantages in term of sen-
sitivity and specificity. In fact, the microscopic
analyses show a detection limit as low as 105
bacilli/mL and only provide information on the
presence of acid-alcohol resistant bacilli.10-12
Culture-based methods remain the gold stan-
dard even though the growth is slow and it may
take 6-8 weeks.13 Substantial shortening of
detection time was realized by use of automat-
ed systems based on liquid culture, such as the
BATEC radiometric method, Septicheck AFB
and MIGIT fluorimetric method.14,15 These
methods are able to reduce the time of diagno-
sis to 1-2 weeks but require dedicated extreme-
ly expensive equipment. DNA amplification
techniques and high-performance liquid chro-
matography provide rapid analyses but require
specialized personnel and are difficult to be
implemented in clinical settings.16-20 Many
studies have focused on M. tuberculosis diagno-
sis based on antigen detection by immune-
based tests, such as dot immunobinding
assay,21 capture enzyme-linked immunosorbent
assay (ELISA),22 and by latex agglutination
assay.23
Several mycobacterial antigens, such as the
38 kDa antigen,24 30 kDa antigen,25 16 kDa
antigen,26 lipoarabinomannan (LAM),27 A60,28
Mtb81,29 55 kDa antigen,22 14 kDa antigen, 19
kDa antigen,30 and ESAT-6,31 have been charac-
terized, purified and, in some cases, reported
for a potential use in the detection of tubercu-
losis.21,22,32,33
Using a dot immunobinding assay, Sumi et
al.21 was able to detect a circulating mycobac-
terial antigen (14 kDa antigen) in cere-
brospinal fluid at the lowest concentration of
100 ng/mL, within 6 h. An ELISA based method
was suggested to detect lipoarabinomannan
antigen (LAM) in human sputum samples.32
The author reported a detection limit of 1
ng/mL using a purified antigen and a concen-
tration of 104 M. tuberculosis whole cells per
mL. Recently, using a Fast Dot-Enzyme-Linked
Immunosorbent Assay (FD-ELISA), El-Masry et
al.33 reported a fast assay which can be applied
in the field for the detection of a 20 kDa
mycobacterium antigen in serum from
patients with pulmonary tuberculosis. This
method was able to detect 1.8 μg/mL of puri-
fied antigen as the lowest detectable concen-
tration. Some of these rapid methods display
high sensitivity but require expensive equip-
ment, training of personnel for their comple-
tion and have not been sufficiently explored in
clinical practice. Moreover this current mark-
ers are not able to differentiate latent and
active tuberculosis disease.34 Among possible
strategies to effectively identify the active
pathogen metabolism is the enzyme involved
in Fe2+ availability in Mycobacteria, such as
the mycobacterial ferredoxin reductase A
(fprA), which seems a promising target to pur-
sue.35 fprA is an NAD(P)H- and FAD-binding
reductase, structurally and evolutionarily relat-
ed to adrenodoxin reductase.36 Two genes,
structurally related to the ferredoxin-NADP+
reductase (FNR) protein family, the flavopro-
tein reductases fprA and fprB, were identified
in M. tuberculosis with the former cloned,
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expressed and purified.37 fprA is involved in
the pathogen metabolism and is thought to
support the activity of several mycobacterial
enzymes.38 Thus, fprA represents a potential
target for antimycobacterial drugs and bacteri-
al viability. In addition, the aminoacidic
sequence of fprA is highly conserved in M.
paratuberculosis, whereas, it differs in other
mycobacteria species (M. leprae, M. avium).
Due to these similarities, the detection of this
protein could provide useful information about
the presence and vitality of bacteria in clinical
and environmental samples.
In the present work, we used a recombinant
fprA protein to set up a rapid and easy method
for diagnosis of Mycobacterium tuberculosis,
based on the lateral flow immunochromatogra-
phy. The rapidity of lateral flow assay was com-
bined to the sensitivity provided by Cadmium
Selenide Quantum Dots (QDs) technology.
QDs are fluorescent semiconductor metal
oxides with high fluorescence intensity and
long photostability.39 QDs, unlike organic dyes,
display different colors corresponding to their
sizes with a single excitation wavelength.40
Materials and MethodsExpression and purification of FprA
fprA recombinant protein was expressed
and purified according to Fischer et al.37 by the
University of Sassari, Department of
Biomedical Science. Total genomic DNA was
isolated from Mycobacterium tuberculosis
(strain H37Rv) using the QIAamp DNA Kit
(Quiagen cat. n. 51304). M. tuberculosis fprA
sequence (Gene ID: 888839) was amplified
from genomic DNA by PCR using the following
oligonucleotide sequences: 5'-GCCATATGAT-
GCGTCCCTATTACA-3’ and 5'-GTCATAT-
GTCAGCCGAGCCCAAT-3', which contained the
Nde I restriction sites (underlined), for subse-
quent cloning of FprA open reading frame into
the pET-11a vector (Novagen cat. n. 69436-3),
according to the procedure described by the
supplier. E. coli BL21(DE3) cells were trans-
formed with pET-FprA plasmid and the recom-
binant FprA protein was expressed and puri-
fied as described by Fischer et al.37Production of monoclonalantibodies against FprA
In order to produce monoclonal antibodies
against the recombinant fprA, mice were
injected intraperitoneosly with 200 μl of anti-
gen (Ag). The immunization scheme was as
follows:
30 μg of antigen were injected at day 0, 30,
60 and 90, followed by a rest period of approxi-
mately 8-14 weeks for maturation to obtain
antibodies with high affinity. Boosting was
performed with 30 μg of antigen in phosphate-
buffered saline (PBS: 10 mM phosphate, 150
mM NaCl, pH 7.5). Hybridoma cell clones were
developed in 7-18 days as described by Leid et
al.41 and were screened by ELISA test against
fprA. Eight clones were selected: 5B8.1; 5G10;
3A10; 2B12; 1A7.1; 2G4; 4H9, and 4E8. The
monoclonal antibodies were produced by
Quattromed Ltd. (Tartu, Estonia).Antibody QD conjugation
The monoclonal antibodies were desalted by
gel filtration with Zeba™ Desalt Spin Columns
(Pierce, cat. n. 89883). The antibodies were
biotinylated using the biotin-XX microscale
protein Kit (Molecular Probes™ cat. no.
B30010) according to the procedure described
by the supplier. The concentration of the
biotinylated antibody was determined at 280
nm by a NanoDrop ND-1000 spectrophotome-
ter (NanoDrop Technologies, Inc.). Cadmium
selenide (CdSe) QDs (15-20 nm in size) with a
maximum emission wavelength of 565 nm,
shelled with ZnS and coupled to streptavidin,
were purchased by Invitrogen (Invitrogen cat.
n. Q10131MP). The amount of 1 μL of QDs 565
streptavidin conjugate was used to label 200 ng
of biotinylated antibody in PBS.Direct LF assay
Hi Flow plus HF135 membrane sheet
(Millipore cat. n. HF13502XSS) was cut into
0.6-0.7 cm wide and 6-7 cm long strips. The
proteins were first desalted by gel filtration
with Zeba™ Desalt Spin Columns and diluted
in PBS before immobilization onto a strip. The
LF test device was prepared as follows (Figure
1A): 1.5 μL of fprA recombinant protein (0.5
μg/μL) was spotted on the membrane as test
line and 1.5 μL of Protein A (1 mg/mL, Sigma)
was spotted as control line. A distance of 1 cm
was chosen between the test and control lines.
After protein spotting, the membrane was
dried at 37° C for 2 h and then assembled on a
glass adhesive backing to provide rigidity.
Cellulose sheet (Millipore cat. n. CFSP173000)
was cut into 0.6-0.7 cm wide and 4-5 cm long
sections and used as sample and adsorbent
pad, respectively applied at the origin of the
sample flow and at the end of the membrane,
overlapping with a 0.4-0.7 cm membrane. One
μL of monoclonal antibody conjugated with
QDs (conjugated clone 4H9 at the concentra-
tion of 0.2 mg/mL) was loaded onto the sample
pad of the lateral flow and then one end of the
strip was immediately dipped in a tube con-
taining the running buffer, allowing the migra-
tion, by capillary forces, along the dipstick into
the adsorbent pad. A positive result was visual-
ized in less than 10 min by the appearance of
two fluorescent lines, both in the test and in
the control area, on a UV lamp (Gel Doc 1000,
Biorad).
Screening the better performingantibodies
Several different monoclonal antibodies
(clones: 5B8.1; 5G10; 3A10; 2B12; 1A7.1; 2G4;
4H9 and 4E8) were used as capture probe and
immobilized onto the test lines of the nitrocel-
lulose strip (two antibodies per strip). The LF
test assay was performed as follows: 1 μL of
the QD conjugated antibody (conjugated clone
4H9 at the concentration of 0.2 mg/mL) was
incubated with 500 ng of fprA recombinant pro-
tein and the mixture was assayed on LF strips.LF sandwich assay
The lateral flow Assay based on double-anti-
body sandwich format was prepared immobi-
lizing 1.5 μL of the monoclonal antibody
(1mg/mL) raised against the fprA recombinant
protein on the test lines. The LF test assay was
performed as follows (Figure 1B): 200 ng of the
QD conjugated antibody (clone 4H9) was incu-
bated with fprA recombinant protein in a final
volume of 40 μL (0.2% Tween-20, 0.2% BSA in
PBS pH 7.4). After 15 min incubation at room
temperature, the mixture was applied onto the
sample pad of the LF and then the bottom tip of
the strip was immediately dipped in the run-
ning buffer, allowing the migration along the
dipstick into the adsorbent pad.
The result of the test was evaluated visually
after 10 min by the UV lamp and the intensity
of the test zone was estimated densitometri-
cally using the software UN-SCAN-IT™ (Silk
Scientific Inc.).
Results and Discussion
Direct LF assays were performed in order to
check the best experimental conditions based
on general protocols (Figure 1A). 
Several different running buffers were test-
ed for the optimum separation of protein com-
plexes along the membrane, the ability to avoid
non-specific adsorption of QDs onto the nitro-
cellulose strip, and for maintaining an appro-
priate pH for physiological stability of QD con-
jugated antibodies.
We also tested different combinations of
three detergents, namely Triton X-100, Tween
20 and SDS, BSA and glycine, for reduce non-
specific adsorption and improved protein sta-
bility and solubility. The best results in terms
of optimal flow rate and sensitivity were
found using a running buffer consisting of
PBS containing 1.5% BSA and 3% Tween-20
(Figure 2D). Lower or higher concentration of
Tween-20 gave high background (Figure 2A)
and fainter fluorescent signals (Figure 2B, C
and E). 
In order to perform the LF assay based on
double-antibody sandwich format (Figure 1B),
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the binding ability of antibodies directed to dif-
ferent fprA domains was screened. 
For this purpose, some different monoclonal
antibodies (clones: 5B8.1; 5G10; 3A10; 2B12;
1A7.1; 2G4; 4H9 and 4E8) were used as capture
probe and immobilized onto the test lines of
the nitrocellulose strip (two antibodies per
strip). 4H9 was QD conjugated and chosen as
detection antibody. The 2G4 antibody showed
the highest fluorescence intensity in compari-
son with other antibodies used as capture
probe. Good but weaker signals were also
recovered form 5G10 and 2B12 antibodies
(Figure 3).
The sensitivity of the LF assay was later
determined. Two hundred ng of QD conjugat-
ed 4H9 antibody was incubated with 0.05, 0.5,
5, 50 and 500 ng of fprA recombinant protein
in a final volume of 40 μl (0.2% Tween-20,
0.2% BSA in PBS) to obtain a final concentra-
tion of 1.25 pg/μL, 12.5 pg/μL, 125 pg/μL, 1.25
ng/μL and 12.5 ng/μL, respectively. After incu-
bation at room temperature for 15 min, the
mixtures were subjected to chromatographic
separation onto LF strips, containing the anti-
body 2G4 in the test line and Protein A in the
control line.
The minimum concentration of fprA pro-
tein, visually detectable on UV lamp, was 125
pg/μL (Figure 4A); however, the densitomet-
ric analysis of the test zones allowed the
detection limit to be lowered to 12.5 pg/μL
(Figure 4B).
Conclusions
We describe a method based on lateral flow
immunochromatographic assay and quantum
dot labeled antibodies as fluorescent tracers.
The device was developed to detect M. tubercu-
losis fprA proteins in liquid samples. In this
experimental condition it was possible to
detect the fprA protein at the lowest dilution of
12.5 pg/μL.
The use of quantum dot labeled antibodies
improved the sensitivity of lateral flow
immunochromatographic assay compared to
other immune-based tests such as ELISA32,33
and dot immunobinding assay.21 However, the
major advantages of the LF are its speed
(results may be available within 15 min) and
simplicity. 
The lateral flow set up in this work showed
the potential to be used as an assay method for
detecting the presence of mycobacterial pro-
teins. The LF device is versatile and could be
implemented with additional antibodies to
detect several mycobacterial antigens impor-
tant in clinics, such as the 38 kDa antigen,24 30
kDa antigen,25 16 kDa antigen,26 lipoarabino-
mannan (LAM),27 A60,28 Mtb81,29 55 kDa anti-
gen,22 14 kDa antigen, 19 kDa antigen,30 and
ESAT-6.31
In fact, the possibility of using antibodies
conjugated with various QDs makes this tech-
nology suitable for multiplexing, allowing the
detection of different antigens in one LF
assay.42 Further work is required in order to
validate the antibodies cross-reactivity towards
different fprA proteins from Mycobacterium
spp. If the diagnostic value of fprA protein is
confirmed, efforts should be focused on the
clinical sample processing, in order to obtain
the best exposure of fprA protein in the lateral
flow assay. 
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Figure 1. Schematic description of immunochromatographic test. (A) Direct lateral flow
assay: QD conjugated antibody solution is applied onto the sample pad of the LF strip,
containing on the test line the fprA recombinant protein and on the control line the
Protein A. (B) Lateral flow assay based on double-antibody sandwich format: QD conju-
gated antibodies are incubated with the sample and then applied onto the sample pad of
the LF strip. The complex QD conjugated antibody-protein is captured on the test line,
by the immobilized antibodies and the excess of QD conjugated antibodies are captured
on the control line, by the immobilized Protein A.
Figure 2. Lateral flow device setup was carried out using the following running buffers:
PBS+BSA +(A) 0.5% Tween-20; (B) 1% Tween-20; (C) 2% Tween-20; (D) 3% Tween-20;
(E) 4% Tween-20.
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